Searchable abstracts of presentations at key conferences in endocrinology

ea0090p386 | Endocrine-related Cancer | ECE2023

Elderly Male with Multiple Endocrine Neoplasia Type 2A: A Diagnostic Journey

Vrckovnik Rok , Kocjan Tomaž

Background: Multiple endocrine neoplasia type 2A (MEN2A) is a rare genetic tumor syndrome due to germline mutations of the RET proto-oncogene, which is characterized by medullary thyroid cancer (MTC), pheochromocytoma (PHEO), and primary hyperparathyroidism (PHPT). The age at onset, aggressiveness of MTC, and the penetrance of other components depend on the genotype. Early prophylactic thyroidectomy and life-long screening for PHEO from childhood are recommended in most cases....

ea0092ps3-25-08 | Case Reports 2 | ETA2023

Resistance to thyroid hormone in the absence of thyroid hormone receptor mutation: A case report

Jesenko Miha , Kocjan Tomaž , Krhin Blaž , Gaberscek Simona

Introduction: Resistance to thyroid hormone beta is a genetic disease defined by impaired sensitivity of target tissue to thyroid hormone caused by mutation of thyroid hormone receptor beta gene, appearing with an incidence of 1/40,000. The characteristic biochemical profile of resistance to thyroid hormone is elevated serum thyroid hormone level and inappropriate serum level of thyrotropin (TSH) which is normal or elevated. Clinical picture is variable ranging from asymptomat...

ea0099p540 | Pituitary and Neuroendocrinology | ECE2024

Pituitary apoplexy – a tertiary centre experience

Rakusa Matej , Bošnjak Roman , Kocjan Tomaž

Background: Pituitary apoplexy (PA) is a rare, potentially life-threatening endocrine emergency, due to abrupt pituitary haemorrhage and/or infarction, usually within a pituitary adenoma. PA most commonly presents with severe headache, visual and oculomotor activity disturbances, nausea/vomiting and/or altered mental status. The outcome is variable and difficult to predict. Most proposed risk factors are hypertension (HTN), diabetes mellitus (DM), and anticoagulant treatment. ...

ea0081rc2.4 | Rapid Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Diagnostic value of basal cortisol level to predict adrenal insufficiency in patients treated with glucocorticoids during COVID-19: a single centre observational cohort study

Jensterle Mojca , Rakusa Matej , Vidmar Gaj , Janez Andrej , Kocjan Tomaž

Objective: During the current pandemic of COVID-19, many therapeutic protocols adopted high dose systemic glucocorticoids (GC) for treatment of moderate to severe respiratory insufficiency. The suppression of the hypothalamic–pituitary–adrenal axis by synthetic GC, even after a short treatment period, cannot be reliably predicted due to pathophysiological changes in cortisol dynamics in critically ill, inter-individual pharmacokinetic differences, and sensitivity var...

ea0081ep208 | Calcium and Bone | ECE2022

Patient with mediastinal mass and hypercalcemia

Mlekus Kozamernik Katarina , Salobir Barbara , Hočevar Marko , Kocjan Tomaž

Introduction: Hypercalcemia is mostly caused by primary hyperparathyroidism and malignancy. Parathyromatosis is a rare condition characterized by multiple nodules of hyperfunctioning parathyroid tissue scattered throughout the neck and superior mediastinum, which can present a diagnostic and therapeutic challenge.Case report: A 56-year-old woman visited the ER due to chest pain, left-sided neck edema, and hematoma. The day before, she experienced left-si...

ea0090p583 | Calcium and Bone | ECE2023

Impact of Zoledronate or Denosumab on Bone-related Biochemical Parameters in Osteoporotic Postmenopausal Women with Primary Hyperparathyroidism

Mlekus Kozamernik Katarina , Ležaić Luka , Hočevar Marko , Kocjan Tomaž

Introduction: Antiresorptive treatment can preserve bone mineral density (BMD) in patients with primary hyperparathyroidism (PHPT) when surgery is not feasible or desired. We aimed to compare the impact of zoledronate vs denosumab on bone-related biochemical parameters in this population.Methods: We analyzed preliminary data from our ongoing randomized trial on osteoporotic postmenopausal women with PHPT who are being treated either with zoledronate 5 mg...

ea0049ep36 | Adrenal cortex (to include Cushing's) | ECE2017

Transformation from Addison’s disease to adrenocortical carcinoma presented as Cushing’s syndrome with androgenisation

Rajic Antonela Sabati , Resman Kristina Groti , Kocjan Tomaž , Pfeifer Marija

We present a female patient 56 years old, who was treated at the endocrinology department from the year 2006. The diagnosis of Addison’s disease was established and she was properly treated. At the same time primary hypothyroidism was diagnosed, also started treating it properly. She was regularly controlled more often at the first time, than yearly at outpatient clinic. In September 2015 she was in menopause. A few months before she noticed oedematous legs and arms and d...

ea0099rc11.1 | Rapid Communications 11: Adrenal and Cardiovascular Endocrinology | Part II | ECE2024

Changing clinical presentation of pheochromocytomas in a tertiary centre

Rakusa Matej , Vidmar Gaj , Silva Ludemila , Gerl Ursa , Kocjan Tomaž

Context: Pheochromocytomas and paragangliomas (PPGLs) are rare tumours with potentially harmful cardiovascular complications. Traditionally, they were detected in patients with symptoms and signs of catecholamine excess or during genetic surveillance. However, according to recent reports, PPGLs are increasingly being diagnosed in the setting of incidentally discovered adrenal masses.Aim: To assess the initial clinical presentation of our PPGL patients wi...

ea0099p247 | Calcium and Bone | ECE2024

More potent antiresorptive effect of denosumab versus zoledronate in osteoporotic postmenopausal women with primary hyperparathyroidism

Kozamernik Katarina Mlekus , Ležaić Luka , Hočevar Marko , Kocjan Tomaž

Introduction: Primary hyperparathyroidism (PHPT) is a state of increased bone turnover that can result in secondary osteoporosis. Antiresorptive treatment can be used to preserve bone mineral density (BMD). We compared the impact of zoledronate and denosumab on bone-related biochemical parameters.Methods: We analyzed interim data from our ongoing randomized trial on osteoporotic postmenopausal women with PHPT who are being treated with either zoledronate...